Bispecific cd 16-binding molecules and their use in the treatment of disease
The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a "CD16 Binding Molecule"). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an e...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; heb |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Gundo DIEDRICH Liqin LIU Leslie S. JOHNSON Hua Watson LI |
| description | The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a "CD16 Binding Molecule"). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen ("DA") (e.g., a "CD16×DA Binding Molecule"). The present invention is particularly directed to such CD16×DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16×DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16×DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL275322A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL275322A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL275322A3</originalsourceid><addsrcrecordid>eNqFyrEKwjAURuEsDqK-gtwX6GCKOqsoCh3dS0z-1AvpTehN318Ed6fDB2dpujNrgefInnyg3aF5sQSWgcac4OcEJSeB6hs80awgli-oTnB1hFTKkQIrnGJtFtElxebXldners_LvUHJPbQ4D0HtH5097ltrT-3f4QPYazOK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Bispecific cd 16-binding molecules and their use in the treatment of disease</title><source>esp@cenet</source><creator>Gundo DIEDRICH ; Liqin LIU ; Leslie S. JOHNSON ; Hua Watson LI</creator><creatorcontrib>Gundo DIEDRICH ; Liqin LIU ; Leslie S. JOHNSON ; Hua Watson LI</creatorcontrib><description>The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a "CD16 Binding Molecule"). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen ("DA") (e.g., a "CD16×DA Binding Molecule"). The present invention is particularly directed to such CD16×DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16×DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16×DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).</description><language>eng ; heb</language><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200730&DB=EPODOC&CC=IL&NR=275322A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200730&DB=EPODOC&CC=IL&NR=275322A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Gundo DIEDRICH</creatorcontrib><creatorcontrib>Liqin LIU</creatorcontrib><creatorcontrib>Leslie S. JOHNSON</creatorcontrib><creatorcontrib>Hua Watson LI</creatorcontrib><title>Bispecific cd 16-binding molecules and their use in the treatment of disease</title><description>The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a "CD16 Binding Molecule"). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen ("DA") (e.g., a "CD16×DA Binding Molecule"). The present invention is particularly directed to such CD16×DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16×DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16×DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyrEKwjAURuEsDqK-gtwX6GCKOqsoCh3dS0z-1AvpTehN318Ed6fDB2dpujNrgefInnyg3aF5sQSWgcac4OcEJSeB6hs80awgli-oTnB1hFTKkQIrnGJtFtElxebXldners_LvUHJPbQ4D0HtH5097ltrT-3f4QPYazOK</recordid><startdate>20200730</startdate><enddate>20200730</enddate><creator>Gundo DIEDRICH</creator><creator>Liqin LIU</creator><creator>Leslie S. JOHNSON</creator><creator>Hua Watson LI</creator><scope>EVB</scope></search><sort><creationdate>20200730</creationdate><title>Bispecific cd 16-binding molecules and their use in the treatment of disease</title><author>Gundo DIEDRICH ; Liqin LIU ; Leslie S. JOHNSON ; Hua Watson LI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL275322A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Gundo DIEDRICH</creatorcontrib><creatorcontrib>Liqin LIU</creatorcontrib><creatorcontrib>Leslie S. JOHNSON</creatorcontrib><creatorcontrib>Hua Watson LI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Gundo DIEDRICH</au><au>Liqin LIU</au><au>Leslie S. JOHNSON</au><au>Hua Watson LI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Bispecific cd 16-binding molecules and their use in the treatment of disease</title><date>2020-07-30</date><risdate>2020</risdate><abstract>The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a "CD16 Binding Molecule"). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen ("DA") (e.g., a "CD16×DA Binding Molecule"). The present invention is particularly directed to such CD16×DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16×DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16×DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; heb |
| recordid | cdi_epo_espacenet_IL275322A |
| source | esp@cenet |
| title | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T18%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Gundo%20DIEDRICH&rft.date=2020-07-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL275322A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |